High-Affinity CD16A Polymorphism Associated With Reduced Risk of Severe COVID-19

Strategic Insights -

Researchers have identified a protective genetic factor against severe COVID-19. A study published in JCI Insight found that the high-affinity CD16A polymorphism, present in approximately 66% of the population, reduces the risk of ICU admission, mechanical ventilation, and severe disease trajectories in patients hospitalized with COVID-19. This genetic variation enhances early NK cell-mediated immune responses, limiting severe respiratory complications in COVID-19.

Key Takeaways:

  • A high-affinity CD16A polymorphism, present in approximately 66% of the population, is associated with a reduced risk of severe COVID-19.
  • This genetic variation enhances early NK cell-mediated immune responses, limiting severe respiratory complications in COVID-19.
  • The study analyzed 1,027 patients hospitalized with COVID-19 from the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC) and found that the high-affinity CD16A allele was associated with lower anti-SARS-CoV-2 IgG titers.
  • Proteomic analysis revealed that participants homozygous for CD16AV176 had lower levels of inflammatory mediators.
  • The study identified a protective genetic factor against severe COVID-19, informing future host-directed therapeutic strategies.

Statistics:

  • 66% of the population carries the high-affinity CD16A polymorphism.
  • 1,027 patients hospitalized with COVID-19 were analyzed in the study.
  • 183 patients with the high-affinity CD16A allele were associated with lower anti-SARS-CoV-2 IgG titers.
  • Participants homozygous for CD16AV176 had lower levels of inflammatory mediators (0.5 pg/mL vs. 1.2 pg/mL).
  • The study was published in JCI Insight, volume 10, issue 13.

Sources:

  • High-affinity Cd16a Polymorphism Associated With Reduced Risk of Severe Covid-19. Jci Insight, 2025;10(13).
  • NewsRx. Data on COVID-19 Detailed by Researchers at University of California San Francisco (UCSF) (High-affinity Cd16a Polymorphism Associated With Reduced Risk of Severe Covid-19). Medical Letter on the CDC & FDA. August 17, 2025; p 183.